Perfuse Therapeutics, Inc.

SAN FRANCISCO, CA · Founded 2018 · Biotech · Acquired

Therapeutic treatment to improve retinal blood flow

Claim this profile

Follows are private to you and power your alerts

Updated · perfusetherapeutics.com

Sector
Biotech
Headquarters
SAN FRANCISCO, CA
Founded
2018
Latest Form D
$9M, Jul 2020
Total capital
$11M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$11M
2 Form D · last Jul 2020
75 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
5
31 pending · first 2023
Rank in peer group#269 of 1449

Capital timeline

20192020FEDERAL ↑EQUITY ↓Cumulative $11M1st Form D$2M2nd Form D$9M
20192020FEDERAL ↑EQUITY ↓Cumulative $11M1st Form D$2M2nd Form D$9M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$9M
  • Private capital raisedForm D · SEC · 1st filing$2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#269 · top 19%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Sevgi GurkanResearcherExecutive Officer, Director, PromoterLinked by 2 patents
  • Chau KhuongDirectorNamed in SEC Form D filings
  • Christy ShafferDirectorNamed in SEC Form D filings
  • Dan BeckerDirectorNamed in SEC Form D filings
  • Hongbo LuDirectorNamed in SEC Form D filings
  • Jerry CagleDirectorNamed in SEC Form D filings

What it has protected

USPTO · 5 granted of 36
Show all 36 patent records
  • Compositions For Treatment Of Ocular DiseasesSep 15, 2026 · US 12,735,411Granted
  • Pharmaceutical Compositions And Intravitreal Drug Delivery Systems For The Treatment Of Ocular DiseasesMay 14, 2026 · Application 19232649Pending
  • Pharmaceutical Compositions And Intravitreal Drug Delivery Systems For The Treatment Of Ocular DiseasesMay 12, 2026 · US 12,622,894Granted
  • Treatment Of Diabetic Retinopathy Using Endothelin Receptor AntagonistsMar 19, 2026 · Application 19397828Pending
  • Treatment Of Diabetic Retinopathy Using Endothelin Receptor AntagonistsMar 27, 2025 · Application 18976033Pending
  • Treatment Of Glaucoma Using Endothelin Receptor AntagonistsJun 13, 2024 · Application 18345514Pending
  • Compositions For Treatment Of Ocular DiseasesApr 4, 2024 · Application 18528378Pending
  • Treatment Of Ocular Diseases Using Endothelin Receptor AntagonistsFeb 22, 2024 · Application 18494545Pending
  • Compositions For Treatment Of Ocular DiseasesJan 16, 2024 · US 11,873,279Granted
  • Pharmaceutical Compositions And Intravitreal Drug Delivery Systems For The Treatment Of Ocular DiseasesOct 17, 2023 · US 11,786,510Granted
  • Treatment Of Glaucoma Using Endothelin Receptor AntagonistsAug 29, 2023 · US 11,738,007Granted
  • Treatment Of Diabetic Retinopathy Using Endothelin Receptor AntagonistsAug 18, 2022 · Application 17733210Pending
  • Compositions For Treatment Of Ocular DiseasesApplication 63010212Pending
  • Compositions For Treatment Of Ocular DiseasesApplication 62971002Pending
  • Treatment Of Ocular Diseases Using Endothelin Receptor AntagonistsApplication 62928092Pending
  • Combination Therapies For Eye Conditions Or DisordersApplication PCTUS2026014756Pending
  • Methods Of Treating Diabetic RetinopathyApplication PCTUS2026014805Pending
  • Methods Of Treating GlaucomaApplication PCTUS2026014739Pending
  • Methods Of Treating GlaucomaApplication 63827799Pending
  • Methods Of Treating Diabetic RetinopathyApplication 63827793Pending
  • Methods Of Treating Diabetic RetinopathyApplication 63783729Pending
  • Methods Of Treating GlaucomaApplication 63756759Pending
  • Combination Therapies For Eye Conditions Or DisordersApplication 63756778Pending
  • Methods Of Treating Diabetic RetinopathyApplication 63756762Pending
  • Methods Of Preparing Drug Delivery Systems Forthe Treatment Of Ocular DiseasesApplication 19596815Pending
  • Methods Of Preparing Drug Delivery Systems For The Treatment Of Ocular DiseasesApplication PCTUS2024060613Pending
  • Methods Of Preparing Drug Delivery Systems For The Treatment Of Ocular DiseasesApplication PCTUS2024060615Pending
  • Methods Of Preparing Drug Delivery Systems For The Treatment Of Ocular DiseasesApplication 63612918Pending
  • Methods Of Preparing Drug Delivery Systems For The Treatment Of Ocular DiseasesApplication 63612913Pending
  • Pharmaceutical Compositions And Intravitreal Drug Delivery Systems For The Treatment Of Ocular DiseasesApplication PCTUS2022027048Pending
  • Treatment Of Ocular Diseases Using Endothelin Receptor AntagonistsApplication PCTUS2022027045Pending
  • Pharmaceutical Compositions And Intravitreal Drug Delivery Systems For The Treatment Of Ocular DiseasesApplication 63287737Pending
  • Treatment Of Ocular Diseases Using Endothelin Receptor AntagonistsApplication 63182750Pending
  • Pharmaceutical Compositions And Intravitreal Drug Delivery Systems For The Treatment Of Ocular DiseasesApplication 63182559Pending
  • Compositions For Treatment Of Ocular DiseasesApplication PCTUS2021016414Pending
  • Treatment Of Ocular Diseases Using Endothelin Receptor AntagonistsApplication 63068215Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .